Managing thrombophilia during pregnancy

References

• James AH. Pregnancy-associated thrombosis. Hematology Am. Soc. Hematol. Educ. Program277–285 (2009).
   PubMedGoogle Scholar
• Chunilal SD, Bates SM. Venous thromboembolism in pregnancy: diagnosis, management and prevention. Thromb. Haemost.101, 428–438 (2009).
   PubMed Web of Science ®Google Scholar
• James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am. J. Obstet. Gynecol.194(5), 1311–1315 (2006).
   PubMed Web of Science ®Google Scholar
• Vora S, Ghosh K, Shetty S, Salvi V, Satoskar P. Deep venous thrombosis in the antenatal period in a large cohort of pregnancies from western India. Thromb. J.5, 9 (2007).
   PubMedGoogle Scholar
• De Stefano V, Rossi E, Za T, Leone G. Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia. Semin. Thromb. Haemost.32, 767–780 (2006).
   PubMed Web of Science ®Google Scholar
• Brenner B. Clinical management of thrombophilia-related placental vascular complications. Blood103, 4003–4009 (2004).
   PubMed Web of Science ®Google Scholar
• Kurasawa G, Kotani K, Ito Y, Saiga K, Lijima K. Reduction in protein S activity during normal pregnency. Aust. N. Z. Obstet. Gynaecol.47(3), 213–215 (2007).
   PubMed Web of Science ®Google Scholar
• Mahieu B, Jacobs N, Mahieu S et al. Haemostatic changes and acquired activated protein C resistance in normal pregnancy. Blood Coagul. Fibrinolysis18(7), 685–688 (2007).
   PubMed Web of Science ®Google Scholar
• Nishii A, Noda Y, Nemoto R et al. Evaluation of D-dimer during pregnancy. J. Obstet. Gynaecol. Res.35(4), 689–693 (2009).
   PubMedGoogle Scholar
• Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br. J. Obstet. Gynecol.102, 191–197 (1997).
   Google Scholar
• Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and post natal risk factors of venous thrombosis: a hospital based case–control study. J. Thromb. Haemost.6, 905–912 (2008).
   PubMed Web of Science ®Google Scholar
• Pabinger I, Grafenhofer H, Kyrle PA et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood100, 1060–1062 (2002).
   PubMed Web of Science ®Google Scholar
• White RH, Chan WS, Zhou H, Ginsberg JS. Recurrent venous thromboembolism after pregnancy-associated versus unprovoked thromboembolism. Thromb. Haemost.100(2), 246–252 (2008).
   PubMed Web of Science ®Google Scholar
• De Stefano V, Martinelli I, Rossi E et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br. J. Haematol.135, 386–391 (2006).
   PubMed Web of Science ®Google Scholar
• Blanco-Molina A, Trujillo-Santos J, Criadi J et al. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE Registry. Thromb. Haemost.97(2), 186–190 (2007).
   PubMed Web of Science ®Google Scholar
• Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb. Haemost.87, 791–795 (2002).
   PubMed Web of Science ®Google Scholar
• Robertson L, Wu O, Langhorne P et al. Thrombophilia and pregnancy: a systematic review. Br. J. Haematol.132(2), 171–196 (2006).
   PubMed Web of Science ®Google Scholar
• MartinelliI, Battaglioli T, De Stefano V et al. The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for the Factor V Leiden and prothrombin G20210 A. J. Thromb. Haemost.6, 494–498 (2008).
   PubMedGoogle Scholar
• Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy and pregnancy: American College of Chest Physicians. Evidence Based Clinical Practice Guidelines (8th Edition). Chest133, 844S–866S (2008).
   PubMed Web of Science ®Google Scholar
• Sarig G, Blumenfeld Z, Leiba R, Lanir N, Brenner B. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb. Haemost.94, 980–985 (2005).
   PubMed Web of Science ®Google Scholar
• Dizon-Townson D, Miller C, Sibai B et al. The relationship of the Factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet. Gynecol.106, 517–524 (2005).
   PubMed Web of Science ®Google Scholar
• Silver RM, Zhao Y, Spong CY et al. Prothrombin gene G20210A mutation and obstetric complications. Obstet. Gynecol.115, 14–20 (2010).
   PubMed Web of Science ®Google Scholar
• Branch DW. The truth about inherited thrombophilias and pregnancy. Obstet. Gynecol.115, 2–4 (2010).
   PubMed Web of Science ®Google Scholar
• Jackson BR, Holmes K, Phansalkar A, Rodgers GM. Testing for hereditary thrombophilia: a retrospective analysis of testing referred to a national laboratory. BMC Clin. Pathol.8, 3 (2008).
   PubMedGoogle Scholar
• Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler. Thromb. Vasc. Biol.24, 1015–1022 (2004).
   PubMed Web of Science ®Google Scholar
• Rousseau A, Favier R, Van Dreden P. Elevated circulating soluable thrombomodulin activity, tissue factor, activity and circulating procoagulant phospholipids: new and useful markers for preeclampsia? Eur. J. Obstet. Gynecol. Reprod. Biol.146, 46–49 (2009).
   PubMed Web of Science ®Google Scholar
• Aharon A, Katzenell S, Tamari T, Brenner B. Microparticles bearing tissue factor and tissue factor pathway inhibitor in gestational vascular complications. J. Thromb. Haemost.7, 1047–1050 (2009).
   PubMedGoogle Scholar
• Erez O, Romero R, Hoppensteadt D et al. Tissue factor and its natural inhibitor in pre-eclampsia and SGA. J. Matern. Fetal Neonatal Med.21, 855–869 (2008).
   PubMed Web of Science ®Google Scholar
• Erez O, Gotsch F, Mazaki-Tovi S et al. Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. J. Matern. Fetal Neonatal Med.22, 672–687 (2009).
   PubMed Web of Science ®Google Scholar
• Pabinger I. Thrombophilia and its impact on pregnancy. Thromb. Res.123, S16–S21 (2009).
   PubMedGoogle Scholar
• van Pampus MG, Dekker GA, Wolf H et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am. J. Obstet. Gynecol.180, 1146–1150 (1999).
   PubMed Web of Science ®Google Scholar
• Caritis S, Sibai B, Hauth J et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal–Fetal Medicine Units. N. Eng. J. Med.338, 701–705 (1998).
   PubMed Web of Science ®Google Scholar
• Wu O, Robertson L, Twaddle S et al. Screening for thrombophilia in high-risk situations: systematic review and cost–effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol. Assess.10(11), 1–110 (2006).
   PubMed Web of Science ®Google Scholar
• Sarig G, Vidergor G, Brenner B. Assessment and management of high-risk pregnancies in women with thrombophilia. Blood Rev.23, 143–147 (2009).
   PubMed Web of Science ®Google Scholar
• Aharon A, Lanir N, Drugan A, Brenner B. Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment. J. Thromb. Haemost.3, 2355–2357 (2005).
   PubMed Web of Science ®Google Scholar
• Gris JC, Mercier E, Quere I et al. Low molecular weight heparin versus low dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood103, 3695–3699 (2004).
   PubMed Web of Science ®Google Scholar
• Brenner B, Bar J, Ellis M et al. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the LIVE-ENOX study. Fertil. Steril.84, 770–773 (2005).
   PubMed Web of Science ®Google Scholar
• Brenner B, Hoffman R, Carp H et al. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J. Thromb. Haemost.3, 227–229 (2005).
   PubMed Web of Science ®Google Scholar
• Monien S, Kadecki O, Baumgarten S, Salama A, Dörner T, Kiesewetter H. Use of heparin in women with early and late miscarriages with and without thrombophilia. Clin. Appl. Thromb. Hemost.15, 636–644 (2009).
   PubMed Web of Science ®Google Scholar
• Qublan H, Amarin Z, Dabbas M et al. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum. Fertil. (Camb.)11, 246–253 (2008).
   PubMedGoogle Scholar
• Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc. Natl Acad. Sci. USA90, 1004–1008 (1993).
   PubMed Web of Science ®Google Scholar
• Bertina RM, Koeleman BC, Koster T et al. Mutation in blood coagulation Factor V associated with resistance to activated protein C. Nature369, 64–67 (1994).
   PubMed Web of Science ®Google Scholar
• Van Stralen KJ, Doggen CJM, Bezemer ID, Pomp ER, Lisman T, Rosendaal FR. Mechanisms of the Factor V Leiden paradox. Arterioscler. Thromb. Vasc. Biol.28, 1872–1877 (2008).
   PubMedGoogle Scholar
• Nusier MK, Radaideh AM, Ababneh NA et al. Prevalence of Factor V G1691A (Leiden) and prothrombin G20210A polymorphisms among apparently healthy Jordanians. Neuro Endocrinol. Lett.28, 699–703 (2007).
   PubMedGoogle Scholar
• Rees DC, Cox M, Clegg JB. World distribution of Factor V Leiden. Lancet346, 1133–1134 (1995).
   PubMed Web of Science ®Google Scholar
• Taylor LJ, Oster RA, Fritsma GA et al. Screening with the activated protein C resistance assay yields significant savings in a patient population with low prevalence of Factor V Leiden. Am. J. Clin. Pathol.129, 494–499 (2008).
   PubMedGoogle Scholar
• Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb. Haemost.102, 360–370 (2009).
   PubMed Web of Science ®Google Scholar
• Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3´-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood88, 3698–3703 (1996)
   PubMed Web of Science ®Google Scholar
• Rosendaal FR, Doggen CJM, Zivelin A et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb. Haemost.79, 706–708 (1997).
   Google Scholar
• Emmerich J, Rosendaal FR, Cattaneo M et al. Combined defect of Factor V Leiden and prothrombin 20210° on the risk of venous thromboembolism – pooled analysis of 8 case–control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb. Haemost.86, 809–816 (2001).
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost.4, 295–306 (2006).
   PubMed Web of Science ®Google Scholar
• Di Simone N, Luigi MP, Marco D. Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature. Ann. NY Acad. Sci.1108, 505–514 (2007).
   PubMed Web of Science ®Google Scholar
• Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood109, 3161–3172 (2007).
   PubMed Web of Science ®Google Scholar
• Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N. Engl. J. Med.309, 340–344 (1983).
   PubMed Web of Science ®Google Scholar
• Reitsma PH, Poort SR, Allaart CF, Briet E, Bertina RM. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. Blood78, 890–894 (1991).
   PubMed Web of Science ®Google Scholar
• Sekiyama K, Itoh H, Sagawa NJ et al. Successful management of a pregnant woman with heterozygous protein C deficiency using activated protein C concentrate. Obstet. Gynaecol. Res.29, 412–415 (2003).
   PubMedGoogle Scholar
• Richards EM, Makris M, Preston FE. The successful use of protein C concentrate during pregnancy in a patient with type 1 protein C deficiency, previous thrombosis and recurrent fetal loss. Br. J. Haematol.98, 660–661 (1997).
   PubMedGoogle Scholar
• Saller F, Brisset AC, Tchaikovski SN et al. Generation and phenotypic analysis of protein S-deficient mice. Blood114, 2307–2314 (2009).
   PubMedGoogle Scholar
• Arkel YS, Ku DH. Thrombophilia and pregnancy: review of the literature and some original data. Clin. Appl. Thromb. Hemost.7, 259–268 (2001).
   PubMed Web of Science ®Google Scholar
• Aldrighi JM, De Campos LS, Eluf Gebara OC, Petta CA, Bahamondes L. Effect of a combined oral contraceptive containing 20 µg ethinyl estradiol and 75 µg gestodene on hemostatic parameters. Gynecol. Endocrinol.22, 1–4 (2006).
   PubMed Web of Science ®Google Scholar
• Olds RJ, Lane DA, Chowdhury V, De Stefano V, Leone G, Thein SL. Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombinantion causing thrombophilia. Biochemistry32, 4216–4224 (1993).
   PubMed Web of Science ®Google Scholar
• La’ulu SL, Rawlins ML, Pfeiffer CM, Zhang M, Roberts WL. Performance characteristics of six homocysteine assays. Am. J. Clin. Pathol.130, 969–975 (2008).
   PubMed Web of Science ®Google Scholar
• Visioli F, Smith A, Zhang W et al. Lipoic acid and vitamin C potentiate nitric oxide synthesis in human aortic endothelial cells independently of cellular glutathione status. Redox Rep.7, 223–227 (2002).
   PubMed Web of Science ®Google Scholar
• Bilsborough W, Green DJ, Mamotte CD, van Bockxmeer FM, O’Driscoll GJ, Taylor RR. Endothelial nitric oxide synthase gene polymorphism, homocysteine, cholesterol and vascular endothelial function. Atherosclerosis169, 131–138 (2003).
   PubMedGoogle Scholar
• Tsai JC, Perrella MA, Yoshizumi M et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc. Natl Acad. Sci. USA91, 6369–6373 (1994).
   PubMed Web of Science ®Google Scholar
• Refsum H, Nurk E, Smith D et al. The Hordaland homocysteine study: a community-based study of homocystein, it’s determinants, and association with disease. J. Nutr.136, 1731S–1740S (2006).
   PubMed Web of Science ®Google Scholar
• McAndrew PE, Brandt JT, Pearl DK, Prior TW. The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African–Americans. Thromb. Res.83, 195–198 (1996).
   PubMedGoogle Scholar
• Jacques PF, Bostom AG, Williams RR et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation93, 7–9 (1996).
   PubMed Web of Science ®Google Scholar
• Gatt A, Makris M. Hyperhomocysteinemia and venous thrombosis. Semin. Hematol.44, 70–76 (2007).
   PubMedGoogle Scholar
• Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Arch. Intern. Med.167, 497–501 (2007).
   PubMedGoogle Scholar
• Ananth CV, Peltier MR, De Marco C et al. Association between two polymorphisms in the methylenetetrahydrofolate reductase gene and placental abruption. Am. J. Obstet. Gynecol.197, 385.e1–e7 (2007).
   Google Scholar
• Lussana F, Dentali F, Abbate R et al. Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb. Res.124, e19–e25 (2009).
   PubMedGoogle Scholar
• Grandone E, Colaizzo D, Brancaccio V, Ciampa A, Di Minno G, Margaglione M. Impact of prothrombotic mutations and family history on the occurrence of intrauterine fetal deaths. Hematologica87, 1118–1119 (2002).
   PubMedGoogle Scholar
• Martinelli I, Battaglioli T, De Stefano V et al. The risk of first venous thromboembolism during pregnency and puerperium in double heterozygotes for Factor V Leiden and prothrombin G20210A. J. Thromb. Haemost.6, 494–498 (2008).
   PubMed Web of Science ®Google Scholar
• Tormene D, Simioni P, Prandoni P et al. The risk of fetal loss in family members of probands with Factor V Leiden mutation. Thromb. Haemost.82, 1237–1239 (1999).
   PubMed Web of Science ®Google Scholar
• Tormene D, De Stefano V, Grandone E et al. The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: a family study. J. Thromb. Haemost.5, 2193–2196 (2007).
   PubMedGoogle Scholar
• Brouwer JL, Veeger NJ, Kluin-Nelemans HC, Van Der MJ. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann. Intern. Med.145, 807–815 (2006).
   PubMed Web of Science ®Google Scholar
• De Stefano V, Martinelli I, Rossi E et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br. J. Haematol.135, 386–391 (2006).
   PubMed Web of Science ®Google Scholar
• Brill-Edwards P, Ginsberg JS, Gent M et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of clot in this pregnancy study group. N. Engl. J. Med.343, 1439–1444 (2000).
   PubMed Web of Science ®Google Scholar
• Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a meta-analysis. J. Rheumatol.33, 2214–2221 (2006).
   PubMed Web of Science ®Google Scholar
• Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst. Rev.18, CD002859 (2005).
   Google Scholar
• Flessa HC, Kapstrom AB, Gluck HI, Will JJ, Miller MA, Brinker BL. Placental transport of heparin. Am. J. Obstet. Gynecol.93, 570–573 (1965).
   PubMed Web of Science ®Google Scholar
• Forestier F, Daffos F, Cappela-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb. Res.34, 557–560 (1984).
   PubMed Web of Science ®Google Scholar
• Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb. Haemost.93, 63–69 (2005).
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Hirsh J, Turner CD, Levine MN, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb. Haemost.61, 197–203 (1989).
   PubMed Web of Science ®Google Scholar
• Lepercq J, Conard J, Borel-Derlon A et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br. J. Obstet. Gynaecol.108, 1134–1140 (2001).
   Google Scholar
• Clark SL, Porter TF, West FG. Coumarin derivatives and breast-feeding. Obstet. Gynecol.95, 938–940 (2000).
   PubMedGoogle Scholar
• Koren G, Klinger G, Ohlsson A. Fetal pharmacotherapy. Drugs62, 757–773 (2002).
   PubMed Web of Science ®Google Scholar
• Kaare M, Ulander VM, Painter JN, Ahvenainen T, Kaaja R, Aittomäki K. Variations in the thrombomodulin and endothelial protein C receptor genes in couples with recurrent miscarriage. Hum. Reprod.22, 864–868 (2007).
   PubMedGoogle Scholar
• Cochery-Nouvellon E, Chauleur C, Demattei C et al. The A6936G polymorphism of the endothelial protein C receptor gene is associated with the risk of unexplained foetal loss in Mediterranean European couples. Thromb. Haemost.102, 656–667 (2009).
   PubMedGoogle Scholar